Friends Research Institute, Inc.
friendsresearch.orgTotal trials
43
Active
9
Phase 3
10
Total enrollment
12,121
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Buprenorphine/Naloxone | — | — | — | — | 2 | ||
| XR-NTX | — | — | — | — | — | 2 | |
| XR-B | — | — | — | — | — | 1 | |
| Methadone Treatment-As-Usual | — | — | — | — | — | 1 | |
| Extended Release Buprenorphine | — | — | — | — | — | 1 | |
| extended-release buprenorphine | — | — | — | — | — | 1 |
Next readouts
- 2024-12-31
- 2026-05-30
- 2026-07-01
- 2027-06-30
- 2029-01-01
Top conditions
- Opioid Use Disorder9
- HIV7
- Opioid-use Disorder5
- Methamphetamine Abuse3
- Cocaine Use Disorder2
- Drug Dependence2
- Drug Abuse2
- Opiate Dependence2
Frequently asked questions about Friends Research Institute, Inc.
- How many clinical trials does Friends Research Institute, Inc. have on ClinicalTrials.gov?
- Friends Research Institute, Inc. is listed as the lead sponsor on 43 clinical trials in ClinicalTrials.gov, 9 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Friends Research Institute, Inc.'s trials are in Phase 3?
- 10 of Friends Research Institute, Inc.'s trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Friends Research Institute, Inc. focus on?
- Friends Research Institute, Inc.'s most-studied conditions on ClinicalTrials.gov are Opioid Use Disorder, HIV, Opioid-use Disorder, Methamphetamine Abuse, Cocaine Use Disorder.
- When are Friends Research Institute, Inc.'s next clinical trial readouts?
- Friends Research Institute, Inc. has 5 upcoming primary-completion readouts tracked here; the soonest is “Low-dose Versus a High-dose Sublingual Buprenorphine Induction”, expected around 2024-12-31.